pacritinib citrate · Sobi · NDA 208712
Vonjo
Earliest generic entry, as listed
25 Mar 2030
Blocked by patent: US 8980873.
Listed patents · 3 unexpired
6 Orange Book listing rows for 3 patents. FDA lists a patent once for each use code, and lists its pediatric extension as a separate row.
| Patent | Claims | Expires |
|---|---|---|
| US 8980873 | drug substance, drug product, use U-3331, U-3332 | 25 Mar 2030 |
| US 8980873 listing row | drug substance, drug product, use U-3331 · sets the listed date | 25 Mar 2030 |
| US 8980873 listing row | drug substance, drug product, use U-3332 · sets the listed date | 25 Mar 2030 |
| US 8153632 | drug substance, drug product, use U-3331, U-3332 | 17 Jan 2029 |
| US 8153632 listing row | drug substance, drug product, use U-3331 | 17 Jan 2029 |
| US 8153632 listing row | drug substance, drug product, use U-3332 | 17 Jan 2029 |
| US 9573964 | use U-3331, U-3332 | 5 May 2028 |
| US 9573964 listing row | use U-3331 | 5 May 2028 |
| US 9573964 listing row | use U-3332 | 5 May 2028 |
Exclusivities · 2 unexpired
| ODE-397 | orphan drug (7 years) | 28 Feb 2029 |
| NCE | new chemical entity (5 years) | 28 Feb 2027 |
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 208712 · 001 · RLD | capsule, oral | EQ 100MG BASE | 25 Mar 2030 |